- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00014170
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)
Aperçu de l'étude
Statut
Description détaillée
OBJECTIVES:
I. Determine treatment effectiveness of gefitinib, in terms of response rate, time to progression, survival at 52 weeks, progression-free survival at 6 months, and overall survival, in patients with newly diagnosed glioblastoma multiforme.
II. Determine the toxic effects of this drug in these patients. III. Assess fatigue, depression, excessive daytime somnolence, and quality of life in patients treated with this drug.
IV. Assess individual variation in responses, pharmacokinetic parameters, and/or biological correlates due to genetic differences in enzymes involved in transport, metabolism, and/or mechanism of action of this drug in these patients.
V. Determine if the type of epidermal growth factor receptor affects tumor response and outcome in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, before each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years.
Patients are followed every 8 weeks until tumor progression and then every 3 months for 5 years and annually for up to 10 years. Patients removed from study treatment for reasons other than disease progression are followed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years.
PROJECTED ACCRUAL: A total of 92 patients will be accrued for this study within 14 months.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- North Central Cancer Treatment Group
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Histologically confirmed newly diagnosed WHO grade IV astrocytoma (glioblastoma multiforme) or gliosarcoma
- No WHO grade III anaplastic astrocytoma, oligodendroglioma, or mixed oligoastrocytoma
Completed standard external beam radiotherapy within the past 2-5 weeks
- No evidence of tumor progression during radiotherapy
- Performance status - ECOG 0-2
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10.0 g/dL
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST no greater than 3 times ULN
- Creatinine no greater than 1.5 times ULN
- No other active malignancy
- No uncontrolled infection
- No other severe concurrent disease that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior chemotherapy (including polifeprosan 20 with carmustine implant) for this tumor
- See Disease Characteristics
- No prior stereotactic radiosurgery or interstitial brachytherapy
- No more than 15 weeks since prior surgery
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Treatment (gefitinib)
Patients receive oral gefitinib daily.
Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
|
Études corrélatives
Donné oralement
Autres noms:
Etudes annexes
Etudes annexes
Autres noms:
Études corrélatives
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Survival
Délai: 52 weeks
|
The proportion of 'successes' will be estimated using the binomial point estimator (number of 'successes' divided by the total number of evaluable patients) and standard binomial 90% confidence interval estimates.
In the unlikely event that accrual has not been completed before the interim analyses are performed, the Duffy-Santner lgorithm will be used to calculate 90% confidence intervals.
|
52 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Post-RT progression-time
Délai: From start of study therapy to date of disease progression or last follow-up, assessed up to 10 years
|
Kaplan-Meier survival curves and logrank tests will be used.
|
From start of study therapy to date of disease progression or last follow-up, assessed up to 10 years
|
Toxicity patterns assessed using NCI CTC version 2.0
Délai: Up to 10 years
|
Will be analyzed descriptively.
Toxicity score calculated as the sum of the maximum toxicity grades recorded for each of the types of adverse reactions observed during the trial.
|
Up to 10 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Joon Uhm, North Central Cancer Treatment Group
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs, glandulaires et épithéliales
- Astrocytome
- Gliome
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Glioblastome
- Gliosarcome
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de protéine kinase
- Géfitinib
Autres numéros d'identification d'étude
- NCI-2012-01855
- U10CA025224 (Subvention/contrat des NIH des États-Unis)
- N0074
- CDR0000068511
- NCCTG-N0074
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur laboratoire d'analyse de biomarqueurs
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Pas encore de recrutement